Coalition Launched Fight Fibrin Sheath Campaign
The initiative aims to address high failure rates in central venous catheters through research and new innovation.
Updated on Sept. 22, 2026 in Heart Disease
Live Poll
Should medical device manufacturers prioritize innovation to solve common, long-term patient complications?
An international coalition has launched the Fight Fibrin Sheath campaign to tackle fibrous protein build-up that restricts blood flow in catheters. The group seeks to unite clinicians, researchers, and device manufacturers to combat this dominant failure mode in catheter care.
Why it matters
Fibrin sheath formation affects nearly all central venous catheters within a week, making it a critical, under-addressed obstacle in clinical management. This effort aims to bridge the gap between long-standing documentation of the problem and modern solutions.
Clinical observations indicate that 80-100% of central venous catheters develop a fibrin sheath within one week of insertion. Currently, 50-75% of dialysis patients initiate their life-saving treatment using a catheter.
The players
Vascular Access Society
This is a professional organization dedicated to education and research concerning vascular access practices for patients.
BioInteractions Ltd.
This is a medical technology company specializing in the development of biocompatible surface coatings for medical devices.
The details
The campaign advocates for innovation in how these medical devices are managed, characterizing existing standards as an unacceptable clinical problem. It brings together stakeholders from the Vascular Access Society and BioInteractions Ltd. to fund research and provide a platform for practitioners to commit to better patient outcomes.
Timeline
The fibrin sheath phenomenon was first documented more than 40 years ago.
The Fight Fibrin Sheath campaign officially launched on September 22, 2026.
Health Landscape
The coalition's collaborative approach to catheter management follows a pattern set by the 2003 SARS response protocols in prioritizing multi-disciplinary intervention for systemic health issues.
For patients undergoing dialysis, this initiative may eventually lead to more reliable catheter technology and reduced treatment interruptions. Clinicians are encouraged to support the effort by signing the campaign's online pledge.
The takeaway
Fibrin sheath formation has persisted as a clinical hurdle for over four decades due to a lack of coordinated focus on innovation. This coalition underscores the necessity of industry and medical cooperation to transition from current management standards to permanent solutions.
Further reading
For additional context on modern vascular management, visit the Heart Disease section.
More information
Learn more about the mission and how to join by visiting the Fight Fibrin Sheath campaign information portal.
Source note: This article includes information reported by News-Medical.
Live Poll
Should medical device manufacturers prioritize innovation to solve common, long-term patient complications?
